Strategic Partnerships Proteocyte AI is actively building strategic advisory relationships with industry experts to guide product development and market entry for Straticyte. Sales teams should target collaboration opportunities with advisory networks and healthcare researchers to accelerate credibility and adoption in clinical settings.

Clinical Validation There is a clear emphasis on validating biomarker-based predictions for cancer risk, supported by collaborations and advisory input. Opportunities exist to position revenue-generating validation studies, pilot programs, and paid research partnerships with hospitals, clinics, and research institutions.

Early Market Entry With Straticyte identified as the first digitally delivered oral cancer predictor, focus sales efforts on early adopters in oncology and dental/otolaryngology spaces, highlighting digital pathology integrations and prognostic imaging to streamline workflows and improve early diagnosis outcomes.

Fundraising & Visibility Historical fundraising activity and ongoing growth signals suggest potential for strategic investors and grant funding collaborations. Business development can pursue co-development, grant-supported studies, and investor-led partnerships to scale technology deployment.

Lean Operations The company currently has a small team, indicating a lean operation with potential capacity constraints but also a quick decision cycle. Sales approaches should emphasize scalable, low-friction pilots, clear ROI, and bundled solutions that minimize implementation burden.